GlassScriptPhysician profile
Jennifer A Bradley
NPI 1013978089
$66,141.77
in general payments reported to CMS, 2019-2025
15 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $7,889 · 2023: $21K · 2024: $3,755 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $1,867 · Food and Beverage: $1,644 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,137.50 |
| Travel and Lodging | $1,867.00 |
| Food and Beverage | $1,644.21 |
| Education | $212.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63,888.53 | 2021-2025 | |
| Allergan, INC. | $1,100.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $320.00 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $212.98 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.91 | 2022-2025 | Caplyta |
| Alkermes, INC. | $125.83 | 2023-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $97.62 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $74.74 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $59.62 | 2022-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $35.94 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $25.02 | 2025 | Trintellix |
| Harmony Biosciences LLC | $20.90 | 2025 | |
| Lundbeck LLC | $17.02 | 2022 | |
| Tris Pharma INC | $16.21 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $14.45 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.